SEC Form 4 · accession 0001209191-15-058900
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Tarriff
Officer — President and CEO · Director · 10% Owner
Period of report
Mar 20, 2015
Accepted (ET)
Jul 2, 2015 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 20, 2015 | S | 120,000 | $42.00 | D | 1,549,622 | D | |
| Common StockF3 | Jul 1, 2015 | S | 4,502 | $81.50 | D | 1,545,120 | D | |
| Common StockF4 | Jul 1, 2015 | S | 1,483 | $80.28 | D | 1,543,637 | D | |
| Common StockF5 | Jul 1, 2015 | S | 6,015 | $78.98 | D | 1,537,622 | D | |
| Common StockF6 | Jul 1, 2015 | S | 3,710 | $77.58 | D | 1,533,912 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were sold pursuant to a prospectus filed on March 17, 2015 with the Securities and Exchange Commission.
- F2These shares were sold pursuant to a Rule 10b5-1 trading plan dated as of June 19, 2015.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $81.19 to $81.63, inclusive. The reporting person undertakes to provide to Eagle Pharmaceuticals, Inc., any security holder of Eagle Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) and in footnotes (4), (5) and (6).
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $80.00 to $80.41, inclusive.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $78.80 to $79.25, inclusive.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $77.12 to $77.96, inclusive.